Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia

Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Decitabine / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Proteins / genetics*
  • Neoplasms, Second Primary / drug therapy
  • Neoplasms, Second Primary / genetics
  • Salvage Therapy
  • Sulfonamides / administration & dosage

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Neoplasm Proteins
  • Sulfonamides
  • Decitabine
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • venetoclax

Associated data

  • ClinicalTrials.gov/NCT03404193